RxDoctor Payments Data

Joshua Shapiro

Medical · New York, NYNPI 1215995642

Payments from drug & device makers

$8,161in general payments, 2019–2025

Across 460 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dermavant Sciences, Inc.$1K
  • AbbVie$1K
  • UCB, Inc.$879
  • Johnson & Johnson$866
  • Sun Pharmaceutical Industries Inc.$838
  • Pfizer$577
  • plus $3K from 16 others

What the payments were for

  • Food & beverage$7,61393%
  • Education$5487%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,161 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$10,171
Medicare patients
32
Services billed
195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab20$249,508
VtamaTapinarof57$77,837
Fluocinonide242$22,124
Metronidazole207$15,497
Clobetasol Propionate156$15,062
ErtaczoSertaconazole Nitrate12$9,774
Calcipotriene43$9,294
QbrexzaGlycopyrronium Tosylate11$6,648
Triamcinolone Acetonide322$5,405
Tacrolimus19$5,384
Clindamycin Phosphate58$5,230
Tranexamic Acid110$3,644
Tretinoin40$3,639
Ketoconazole90$3,544
Minoxidil138$3,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$866$249,50820 claims
Dermavant Sciences, Inc.Vtama$1,299$77,83757 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,395 medical providers in New York.

Other medical in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →